German pharmaceutical giant BioNTech has reached an agreement to acquire its rival CureVac in an all-stock transaction valued at $1.25 billion, a move that resolves ongoing patent disputes between the two messenger RNA companies just weeks before their scheduled court appearance.
Under the terms announced Thursday, CureVac shareholders will receive BioNTech shares worth approximately $5.46 for each CureVac share they hold. Once the acquisition is completed, CureVac stockholders will control between 4% and 6% of BioNTech.
The deal comes after a complex history between the two companies, which were both early contenders in the race to develop COVID-19 vaccines. While BioNTech successfully partnered with Pfizer to create the first approved coronavirus vaccine, CureVac’s vaccine candidate failed to demonstrate sufficient efficacy in clinical trials, leading to its eventual abandonment.
Following these divergent paths, CureVac initiated patent infringement litigation against BioNTech, claiming violations of four patents. The legal battle was approaching a critical juncture, with a trial scheduled for July 1 in a Dusseldorf regional court and another proceeding set for September 8 in Virginia.
Industry analysts suggest the acquisition may have been primarily motivated by BioNTech’s desire to avoid potentially costly litigation outcomes. According to Evercore ISI analyst Umer Raffat, BioNTech could have faced up to $3 billion in royalty payments had CureVac prevailed in court. Raffat noted that BioNTech likely determined that acquiring CureVac outright would be less expensive than settling the patent disputes.
Beyond resolving legal conflicts, the merger also strengthens BioNTech’s oncology research portfolio. Both companies have made cancer treatment development a strategic priority, though their programs are at different stages. While BioNTech has advanced several cancer-fighting technologies, including cell therapies and mRNA vaccines, CureVac’s oncology programs remain in earlier development phases.
CureVac has shown promising initial results with its brain cancer vaccine and recently received approval to begin human trials for a lung cancer immunotherapy. However, Leerink Partners analyst Mani Foroohar suggests that CureVac will benefit from BioNTech’s expertise in personalized cancer vaccines, noting that CureVac needed a development partner to effectively compete in this space.
The acquisition represents a significant shift for CureVac, which has already undergone substantial strategic changes in recent years. After its COVID-19 vaccine setback, the company sold most of its rights to influenza and COVID-19 vaccines to GSK and redirected its focus toward cancer research.
The European Patent Office had previously upheld two of CureVac’s patents in the ongoing dispute with BioNTech. This validation of CureVac’s intellectual property claims may have influenced the timing and structure of the acquisition deal.
Despite the strategic benefits of the merger, some analysts, including Raffat, have observed that the deal terms assign minimal value to CureVac’s development pipeline. This assessment suggests that the primary driver of the acquisition may indeed have been the resolution of patent disputes rather than the potential of CureVac’s drug candidates.
The transaction marks a significant consolidation in the mRNA therapeutics field, bringing together two pioneering companies that have helped advance this innovative technology platform, particularly during the global pandemic response.
Be First to Comment